INTEGRA Biosciences strengthened market position in 2025
Laboratory equipment manufacturer defies customs costs and grows by 3 percent on a currency-adjusted basis
Advertisement
The 2025 financial year presented INTEGRA Biosciences AG with exceptional economic and geopolitical challenges. Despite a difficult global market, the company successfully held its own, thanks to a robust business model and consistent implementation of its long-term strategy.
The SWITCH is the world's first hybrid pipette that combines manual control and electronic efficiency in a single device.
INTEGRA Biosciences
External pressures in 2025 brought considerable challenges for INTEGRA. Customs duties on precision instruments shipped from Zizers to the US had a noticeable impact on the cost structure. In addition, strong currency fluctuations and global reluctance to invest in research and development – especially in the US – placed considerable demands on the company. Thanks to our high adaptability, flexible organization and clear focus on factors we can influence, we were able to successfully overcome these challenges.
At first glance, there was a slight decline in sales in Swiss francs of around 1 percent below the previous year's level. However, when adjusted for currency effects, we achieved solid growth of 3 percent. In a tumultuous year, this was an outstanding achievement, and one that we are very proud of. Business developed particularly well in Europe, where we recorded high single-digit growth, and sales in local currency also increased in the US. Meanwhile, strong competition from local suppliers continued in China and Japan.
“Our resilience in this challenging environment shows that we are strategically well positioned,” commented Urs Hartmann, CEO of INTEGRA Biosciences.
Strong position thanks to innovation and consistent strategy
Despite the difficult conditions, we were able to achieve success by focusing on innovation and strategic development in 2025. The launch of the SWITCH hybrid pipette brought a new generation of pipettes to the global market. This unique hybrid pipette combines precise manual control and fast electronic aliquoting in a single device, accelerating routine processes in the laboratory. We also increased our product portfolio with MAGFLO™ NGS magnetic beads for NGS size selection and PCR purification. These innovations provide customers with noticeable efficiency gains in everyday laboratory work. Our ability to consistently deliver solutions that make real world differences to laboratories despite external pressures underscores our technological leadership.
Investing in the future
We also achieved significant milestones beyond product launches. Our cooperation with CleanNA strengthened in 2025 as we invested further in the company. In doing so, we support the joint development of innovative reagents for our molecular biology customers. At the same time, we introduced a new global corporate planning system. This uniform platform is available in all countries, provides efficiency gains and creates the basis for further process optimization.
Looking to the future
We are cautiously optimistic about the outlook for 2026. The economic climate is uncertain, but we have already put measures in place to compensate for custom costs, so that we can still provide US customers with the same great products. We also have several new products set to launch very soon, which should offset the effects of the continuing weakening of the US dollar. We are also investing in the next generation of young talent. We currently have 23 apprentices, who are making important contributions to the future of INTEGRA Biosciences.
“Our strength lies in the combination of innovative power, team spirit, and long-term thinking,” emphasized Urs Hartmann. “This means we are well prepared to remain successful in a persistently volatile environment.”
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Pipetting
Pipetting is one of the most basic yet critical techniques in the laboratory. It enables the precise and controlled transfer of liquids, which is essential for accurate measurements and reliable results. Whether in DNA analysis, cell culture or biochemical assays, correct pipetting significantly influences the quality of the results.
Topic world Pipetting
Pipetting is one of the most basic yet critical techniques in the laboratory. It enables the precise and controlled transfer of liquids, which is essential for accurate measurements and reliable results. Whether in DNA analysis, cell culture or biochemical assays, correct pipetting significantly influences the quality of the results.